Copanlisib Dihydrochloride Patent Expiration
Copanlisib Dihydrochloride is Used for treating relapsed follicular lymphoma in adult patients who have not responded to at least two prior systemic therapies. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Copanlisib Dihydrochloride Patents
Given below is the list of patents protecting Copanlisib Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aliqopa | US10383876 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | Mar 29, 2032 | Bayer Healthcare |
| Aliqopa | US9636344 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts | Mar 29, 2032 | Bayer Healthcare |
| Aliqopa | US8466283 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Oct 22, 2029 | Bayer Healthcare |
| Aliqopa | USRE46856 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Oct 22, 2029 | Bayer Healthcare |
| Aliqopa | US7511041 | Fused azole-pyrimidine derivatives |
May 13, 2024
(Expired) | Bayer Healthcare |
Copanlisib Dihydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List